Lenalidomide and low-dose dexamethasone for newly diagnosed primary plasma cell leukemia.
about
Molecular Classification and Pharmacogenetics of Primary Plasma Cell Leukemia: An Initial Approach toward Precision MedicinePrimary plasma cell leukemia 2.0: advances in biology and clinical management.Trends in survival of patients with primary plasma cell leukemia: a population-based analysis.Whole-exome sequencing of primary plasma cell leukemia discloses heterogeneous mutational patterns.Prognostic impact of circulating plasma cells in patients with multiple myeloma: implications for plasma cell leukemia definition.Incidence, characteristics, and outcome of solitary plasmacytoma and plasma cell leukemia. Population-based data from the Swedish Myeloma Register.A compendium of DIS3 mutations and associated transcriptional signatures in plasma cell dyscrasias.Molecular spectrum of BRAF, NRAS and KRAS gene mutations in plasma cell dyscrasias: implication for MEK-ERK pathway activation.Plasma cell leukemia: from biology to treatment.Primary Plasma Cell Leukemia: Identity Card 2016.Activation of NK cells and disruption of PD-L1/PD-1 axis: two different ways for lenalidomide to block myeloma progressionMolecular spectrum of TP53 mutations in plasma cell dyscrasias by next generation sequencing: an Italian cohort study and overview of the literature.The role of frontline autologous stem cell transplantation for primary plasma cell leukemia: a retrospective multicenter study (KMM160).Prognostic indicators in primary plasma cell leukaemia: a multicentre retrospective study of 117 patients.Real-world data on prognosis and outcome of primary plasma cell leukemia in the era of novel agents: a multicenter national study by the Greek Myeloma Study Group.Plasma cell leukemia: update on biology and therapy.Retrospective analysis of primary plasma cell leukemia in Kansai Myeloma Forum registry.
P2860
Q26799238-4941810D-AE7F-4E77-9250-85CC03B3DB40Q30243927-AE0A9A59-DE29-4B32-8ECF-54A4A89CBFE2Q34019590-70E4273A-0EDD-410F-A3C4-46B2B5A54949Q34479418-631397FC-C9D6-415B-9E3E-1083B2DDE798Q34552588-D6DB2B9D-4E26-4192-B83D-D4C1846500D0Q36381306-2635677D-EA16-4A0D-8A49-2DA121998CBCQ36413387-25958386-7BDD-40F4-93F4-5A7279C76D38Q36414422-6D2F10F6-068F-41E1-AF5C-DB65812A1457Q38380625-26282AE6-E343-448B-AEB3-A2BEAC5FFE2AQ38781794-0454EB21-2097-44D6-9E4A-06AEA901624AQ39136762-12F90BF5-F2E4-45F6-B9AF-7636265AFB1EQ40002181-D6577C45-C030-471E-BDED-3998BDE2E797Q47140962-B0403653-3302-4E18-BDD7-6829051CC7D0Q48283707-D261784E-934E-4F57-89BD-8E34771F6FCAQ52663601-74B62EFF-268B-4C56-989A-83FB3124CB53Q52838137-A66A6E19-B12A-4BB2-A848-9AC8C98D521FQ55714690-BB7D8FFD-DD4E-40E2-A2FE-BF885D222047
P2860
Lenalidomide and low-dose dexamethasone for newly diagnosed primary plasma cell leukemia.
description
2013 nî lūn-bûn
@nan
2013年の論文
@ja
2013年学术文章
@wuu
2013年学术文章
@zh
2013年学术文章
@zh-cn
2013年学术文章
@zh-hans
2013年学术文章
@zh-my
2013年学术文章
@zh-sg
2013年學術文章
@yue
2013年學術文章
@zh-hant
name
Lenalidomide and low-dose dexamethasone for newly diagnosed primary plasma cell leukemia.
@en
Lenalidomide and low-dose dexamethasone for newly diagnosed primary plasma cell leukemia.
@nl
type
label
Lenalidomide and low-dose dexamethasone for newly diagnosed primary plasma cell leukemia.
@en
Lenalidomide and low-dose dexamethasone for newly diagnosed primary plasma cell leukemia.
@nl
prefLabel
Lenalidomide and low-dose dexamethasone for newly diagnosed primary plasma cell leukemia.
@en
Lenalidomide and low-dose dexamethasone for newly diagnosed primary plasma cell leukemia.
@nl
P2093
P2860
P50
P356
P1433
P1476
Lenalidomide and low-dose dexamethasone for newly diagnosed primary plasma cell leukemia.
@en
P2093
A Olivieri
F Morabito
G Benevolo
G Mansueto
P2860
P2888
P304
P356
10.1038/LEU.2013.241
P577
2013-08-20T00:00:00Z